Floatz logo

NORAMITRIPTYLINE

Depressive Disorder

University College, LondonSmall moleculePhase 4 / ApprovedDormant
BB
70/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
68/ 100
Competitive Position
73/ 100

Competitive context

78 Active assets in the Depressive Disorder cohort.

Asset / SponsorPhaseRating
Opc-34712
Dr. Albert Kar-Kin Chung
Phase 4A
S-Ketamine
Chinese PLA General Hospital
Phase 4BBB
Saredutant
Sanofi
Phase 3BBB
LITHIUM, ELEMENTAL
Rakitzi, Stavroula
Phase 4BBB
CITALOPRAM
Western University, Canada
Phase 4BBB

View all 50 →

Same molecule, other indications

NORAMITRIPTYLINE is also rated in:

Treatment-Refractory DepressionDormant
BB
Indicative ·
69 / 100
View asset →
dementiaDormant
BB
Indicative ·
65 / 100
View asset →
Headaches PosttraumaticDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →